Publications by authors named "David Allsup"

Claim this Profile
F
Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care.
Stefano Molica, David Allsup

Expert Rev Anticancer Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions | The Evolving Landscape of Prognostic Models in Chronic Lymphocytic Leukemia.
Stefano Molica, Ahmad Ibrahim, David Allsup

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Talha Munir, Sean Girvan, David A Cairns, Adrian Bloor, David Allsup

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.
Stefano Molica, David Allsup

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How should abnormal uterine bleeding be managed in people with bleeding disorders: a systematic review of the literature and thematic synthesis.
Rameen Masood, Vidiya Dev, Millie Gee, Katie Finch, Daniel M Fletcher, David Allsup

Res Pract Thromb Haemost· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.
Stefano Molica, Tait D Shanafelt, Diana Giannarelli, David Allsup

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View.
Stefano Molica, David Allsup

Mediterr J Hematol Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.
Stefano Molica, David Allsup

Expert Rev Anticancer Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed Duration Ibrutinib-Venetoclax, a Redefinition of the CLL Treatment Landscape.
Stefano Molica, David Allsup

Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia.
Fisal Tantoush, David Allsup, Leigh Naylor-Adamson, Frank Voncken, Stefano Caserta

Front Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta-Analysis.
Stefano Molica, David Allsup, Diana Giannarelli

Am J Hematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation.
Leigh Naylor-Adamson, Thomas W Price, Zoe Booth, Sophie V L Leonard, Juan Gallo, David Allsup

J Mater Chem B· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.
Stefano Molica, David Allsup

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib-Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.
Daniel James, Simone Green, Stefano Molica, David Allsup

Case Rep Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.
Stefano Molica, David Allsup, Diana Giannarelli

Am J Hematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How can we optimize antifungal use and stewardship in the treatment of acute leukemia?
Thomas Taynton, David Allsup, Gavin Barlow

Expert Rev Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.
Lydia Flett, Radwa Abdelatif, Sarah Akhtar Baz, Samantha Brady, Belén Corbacho, David Allsup

Trials· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.
Stefano Molica, Marco Rossi, David Allsup

Acta Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets.
Hélio M Gil, Zoe Booth, Thomas W Price, Jessica Lee, Leigh Naylor-Adamson, David Allsup

Small· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.
Stefano Molica, Tait D Shanafelt, David Allsup, Diana Giannarelli

Am J Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.
Stefano Molica, Tait D Shanafelt, David Allsup, Diana Giannarelli

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epcoritamab in B-cell malignancies: current status and prospects.
Stefano Molica, Marco Rossi, David Allsup

Expert Opin Biol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Stefano Molica, Constantine Tam, David Allsup, Aaron Polliack

Hematol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Talha Munir, David A Cairns, Adrian Bloor, David Allsup, Kate Cwynarski

N Engl J Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, Anargyros Kapetanakis, Christos Demosthenous, David Allsup

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis